Heparin-induced thrombocytopenia: treatment options and special considerations.

Dager, William E; Dougherty, John A; Nguyen, Phuong H; Militello, Michael A; Smythe, Maureen A

Dager, William E; Dougherty, John A; Nguyen, Phuong H; Militello, Michael A; Smythe, Maureen A.

Affiliation

Dager WE; Department of Pharmaceutical Services, University of California-Davis Medical Center, California 95817-2201, USA. william.dager@ucdmc.ucdavis.edu

Pharmacotherapy ; 27(4): 564-87, 2007 Apr.

Article in En | MEDLINE | ID: mdl-17381384

Subject(s)

Heparin/adverse effects; Thrombocytopenia/chemically induced; Anticoagulants/administration & dosage; Anticoagulants/adverse effects; Antithrombins/therapeutic use; Arginine/analogs & derivatives; Heparin/administration & dosage; Hirudins; Humans; Peptide Fragments/therapeutic use; Pipecolic Acids/therapeutic use; Recombinant Proteins/therapeutic use; Sulfonamides; Thrombocytopenia/diagnosis; Thrombocytopenia/drug therapy; Thrombosis/chemically induced; Thrombosis/diagnosis; Thrombosis/drug therapy

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thrombocytopenia / Heparin Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Pharmacotherapy Year: 2007 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links